Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 3/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | CCR8 | P51685 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL590041 | 0.86 | LMNA (0.43) | HTR1AADRA1DADRA1AADRA1BKDM4E | |
| SCHEMBL9900652 | 0.78 | NPC1 (0.38) | LMNARAB9AMEN1NPC1KMT2A | |
| SCHEMBL4471481 | 0.76 | ALDH1A1 (0.46) | HTR1AADRA1DADRA1AADRA1BKDM4E | |
| SCHEMBL197798 | 0.74 | PDGFRB (0.46) | KDM4EALDH1A1NQO2SMN1; SMN2EGFR | |
| SCHEMBL7435881 | 0.74 | PDGFRB (0.42) | HTR1AADRA1DADRA1AADRA1BKDM4E | |
| SCHEMBL217998 | 0.73 | NR4A2 (0.47) | MEN1KMT2ACCR1PDGFRBPDGFRA | |
| SCHEMBL29550130 | 0.72 | KDM4E (0.56) | HTR1AADRA1DADRA1AADRA1BKDM4E | |
| SCHEMBL622115 | 0.72 | KDM4E (0.56) | HTR1AADRA1DADRA1AADRA1BKDM4E | |
| SCHEMBL6048370 | 0.72 | CA1 (0.43) | KDM4ELMNARAB9AMEN1NPC1 | |
| SCHEMBL855089 | 0.72 | FERMT2 (0.35) | KDM4EMEN1ALDH1A1KMT2APDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090593-B2 | Bicyclic compounds as Pim inhibitors | AMGEN INC. (US) | 2015-07-28 | — | — | US | claimed |
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2014-01-30 | — | — | US | claimed |
| EP-2649065-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | Amgen Inc. (US) | 2013-10-16 | — | — | EP | claimed |
| WO-2012078777-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-06-14 | — | — | WO | claimed |
| US-20120070413-A1 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES | KIM TAE-SEONG (US) | 2012-03-22 | — | — | US | claimed |
| US-6777543-B2 | MACROLIDE COMPOUNDS USEFUL AS ANTIBACTERIAL AND ANTIPROTOZOAL AGENTS IN MAMMALS, INCLUDING MAN, FISH AND BIRDS | PFIZER, INC. | 2004-08-17 | — | — | US | claimed |
| US-20030229031-A1 | 13-Methyl erythromycin derivatives | PFIZER INC. | 2003-12-11 | — | — | US | claimed |
| US-20030100518-A1 | 13-Methyl erythromycin derivatives | PFIZER, INC. | 2003-05-29 | — | — | US | claimed |
| US-20030100742-A1 | Useful as antibacterial and antiprotozoal agents in mammals, fish and birds; contains a carbamate-containing fused ring | PFIZER INC. | 2003-05-29 | — | — | US | claimed |
| EP-1180110-A1 | 13-METHYL-ERYTHROMYCIN DERIVATIVES | Pfizer Products Inc. (US) | 2002-02-20 | — | — | EP | claimed |
| EP-1146051-A2 | Erythromycin A derivatives | Pfizer Products Inc. (US) | 2001-10-17 | — | — | EP | claimed |
| WO-2000071557-A1 | 13-METHYL-ERYTHROMYCIN DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2000-11-30 | — | — | WO | claimed |
| US-20240101545-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER | GUANGZHOU INNOCARE PHARMA TECH CO LTD (CN) | 2024-03-28 | — | — | US | disclosed |
| US-11840513-B2 | Substituted nicotinimide inhibitors of BTK for treating cancer | Guangzhou Innocare Pharma Tech Co., Ltd (CN) | 2023-12-12 | — | — | US | disclosed |
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| CN-115996912-A | Iminothiolanone inhibitors of ENPP1 | 沃拉斯查疗法公司 | 2023-04-21 | — | — | CN | disclosed |
| US-20030100518-A1 | 13-Methyl erythromycin derivatives | PFIZER, INC. | 2003-05-29 | — | — | US | disclosed |
| EP-1180110-A1 | 13-METHYL-ERYTHROMYCIN DERIVATIVES | Pfizer Products Inc. (US) | 2002-02-20 | — | — | EP | disclosed |
| EP-1146051-A2 | Erythromycin A derivatives | Pfizer Products Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000071557-A1 | 13-METHYL-ERYTHROMYCIN DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | ENPP1, ENPP3, SMPD1 | HTR1A 2850/4885ADRA1D 3743/4885ADRA1A 4272/4885 |
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | PIM1, PIM2, PIM3 | HTR1A 4053/4885ADRA1D 2576/4885ADRA1A 2915/4885 |
| US-20030100518-A1 | 13-Methyl erythromycin derivatives | RPS4Y1, MRPL21, CYP2F1 | HTR1A 765/4885ADRA1D 764/4885ADRA1A 665/4885 |
| US-20240101545-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER | BTK, SYK, LYN | HTR1A 4263/4885ADRA1D 4495/4885ADRA1A 4266/4885 |
| US-20120070413-A1 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES | HGF, HGFAC, MET | HTR1A 4021/4885ADRA1D 3126/4885ADRA1A 2207/4885 |
| US-20030100742-A1 | Useful as antibacterial and antiprotozoal agents in mammals, fish and birds; contains a carbamate-containing fused ring | CASP1, CPS1, CASP10 | HTR1A 2312/4885ADRA1D 2355/4885ADRA1A 2544/4885 |
| US-20030229031-A1 | 13-Methyl erythromycin derivatives | RPS4Y1, MRPL21, CYP2F1 | HTR1A 765/4885ADRA1D 764/4885ADRA1A 665/4885 |
| US-11840513-B2 | Substituted nicotinimide inhibitors of BTK for treating cancer | BTK, SYK, LYN | HTR1A 4263/4885ADRA1D 4495/4885ADRA1A 4266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.